Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising through debt or equity in the provided transcript from the Zensar Technologies Q1 FY'25 earnings call. The management focuses mainly on operational performance, growth by verticals, margin outlook, and acquisitions like BridgeView Life Sciences. The company reported strong financial health with increased cash and cash equivalents ($280.9 million) and improved DSOs. There is no indication or discussion related to plans for raising funds via debt or equity in the available content.

Any current/future capex/capital investment/strategic investment?

Zensar Technologies has made a strategic investment by acquiring BridgeView Life Sciences, a Pennsylvania-based technology and consulting solutions company specializing in the pharmaceutical commercial segment. This acquisition enhances Zensar's focus on the Healthcare and Life Sciences vertical and strengthens their end-to-end pharmaceutical commercial quality and regulatory capabilities. The company continues to invest in key verticals such as BFSI, Healthcare, and Life Sciences, focusing on strategic areas that offer quick returns and align with their growth goals. There is an emphasi

Future growth expectations in sales/revenue/volumes?

Zensar Technologies is positive about growth across all verticals, with sequential growth reported in two consecutive quarters. For FY '25, the company expects continued momentum in its verticals including Telecom, BFSI, Healthcare, and Life Sciences. There is an aspiration to be in line with industry growth this year and aim for leadership in growth rates next year. The large deal pipeline is improving, with anticipation to convert 1-2 large deals in FY '25. Despite some headwinds like furloughs and bankruptcy impacts, the company remains cautiously optimistic about maintaining around 4% sequ

Future growth expectations in earnings/operating earnings/profits/EPS?

Zensar aspires to be in line with industry growth in the current year and aims to be in the leaders' quadrant for growth rates next year. Sequential revenue growth has been observed across all verticals for two consecutive quarters, with positive momentum expected to continue. BFSI vertical has shown strong and continued growth, with hopes for sustainment due to larger ongoing projects. Margin outlook remains mid-teens EBITDA margins, with efforts underway to mitigate impacts of wage hikes and operational costs to maintain margins. The acquisition of BridgeView Life Sciences is not exp

Current/ Expected Orderbook/ Pending Orders?

Q1 FY'25 order book stood at $154 million. Order bookings in the current quarter are almost flat year-on-year, considered a good sign. Last quarter, order bookings were around $180 million, some of which is reflected in the current quarter. Pipeline is described as "okay" with a lag in order booking due to previous large bookings. Company remains cautiously optimistic about Q2 based on order bookings and pipeline. Management is actively pursuing at least 1 or 2 large deals in FY'25 from the existing pipeline. Book-to-bill ratio for the current quarter is 1, indicating orders equal

Zensar Technologies LtdQ1 FY25IT - Software

Zensar Technologies Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹429P/E: 12.4Market Cap: ₹9.9K CrSector: IT - Software

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

Zensar Technologies is positive about growth across all verticals, with sequential growth reported in two consecutive quarters.
For FY '25, the company expects continued momentum in its verticals including Telecom, BFSI, Healthcare, and Life Sciences.
There is an aspiration to be in line with industry growth this year and aim for leadership in growth rates next year.
The large deal pipeline is improving, with anticipation to convert 1-2 large deals in FY '25.
Despite some headwinds like furloughs and bankruptcy impacts, the company remains cautiously optimistic about maintaining around 4% sequential revenue growth.
Sector-wise, BFSI is showing strong and sustained recovery with positive momentum; TMT had some softness recently but is expected to stabilize.
South Africa remains a strategic geography with good volume growth despite currency fluctuations.
Overall, the focus on cross-selling, capability building, and strategic acquisitions (e.g., BridgeView Life Sciences) supports growth expectations.

Margin guidance

Category 3

Zensar aspires to be in line with industry growth in the current year and aims to be in the leaders' quadrant for growth rates next year.
Sequential revenue growth has been observed across all verticals for two consecutive quarters, with positive momentum expected to continue.
BFSI vertical has shown strong and continued growth, with hopes for sustainment due to larger ongoing projects.
Margin outlook remains mid-teens EBITDA margins, with efforts underway to mitigate impacts of wage hikes and operational costs to maintain margins.
The acquisition of BridgeView Life Sciences is not expected to be margin or EPS dilutive this year.
Management remains committed to delivering quarter-on-quarter growth and improving operational efficiencies to support earnings growth.
Pipeline and order book are stable, with ongoing efforts to convert large deals for future growth.

See what Zensar Technologies Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or future fundraising through debt or equity in the provided transcript from the Zensar Technologies Q1 FY'25 earnings call.
The management focuses mainly on operational performance, growth by verticals, margin outlook, and acquisitions like BridgeView Life Sciences.
The company reported strong financial health with increased cash and cash equivalents ($280.9 million) and improved DSOs.
There is no indication or discussion related to plans for raising funds via debt or equity in the available content.

Order book

Yes

Q1 FY'25 order book stood at $154 million.
Order bookings in the current quarter are almost flat year-on-year, considered a good sign.
Last quarter, order bookings were around $180 million, some of which is reflected in the current quarter.
Pipeline is described as "okay" with a lag in order booking due to previous large bookings.
Company remains cautiously optimistic about Q2 based on order bookings and pipeline.
Management is actively pursuing at least 1 or 2 large deals in FY'25 from the existing pipeline.
Book-to-bill ratio for the current quarter is 1, indicating orders equal to revenue.
Despite headwinds like cybersecurity issues and furloughs, the company expects steady momentum.

See what Zensar Technologies Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Zensar Technologies has made a strategic investment by acquiring BridgeView Life Sciences, a Pennsylvania-based technology and consulting solutions company specializing in the pharmaceutical commercial segment.
This acquisition enhances Zensar's focus on the Healthcare and Life Sciences vertical and strengthens their end-to-end pharmaceutical commercial quality and regulatory capabilities.
The company continues to invest in key verticals such as BFSI, Healthcare, and Life Sciences, focusing on strategic areas that offer quick returns and align with their growth goals.
There is an emphasis on talent transformation and capability building, including investments in training, cross-training, and onboarding fresh talent to support business growth.
No specific future capex numbers were disclosed in the provided transcript, but management indicated ongoing investments for growth across strategic geographies like South Africa and in areas such as AI, GenAI, Data Engineering, and Cloud services.

Track Zensar Technologies Ltd — get its next earnings analysis in your feed

How does Zensar Technologies Ltd rank vs peers in IT - Software?

Pro feature

ThisZensar Technologies Ltd

Rev 4Mar 3

See where Zensar Technologies Ltd sits in IT - SoftwareSee which companies these are, and every other name in the sector.Open rankings

How does Zensar Technologies Ltd rank in IT - Software?

Compare Zensar Technologies Ltd against every IT - Software company (Q1 FY25) on revenue, margins and earnings-call signals.

View IT - Software leaderboard →

What Zensar Technologies Ltd's management said in earlier quarters

Others in IT - Software this season

Workmates Core2cloud Solution Ltd (Q1 FY27)
FY26 total revenue: ₹143 Cr (Page 10) . Key concall takeaways from Workmates Core2cloud Solution Ltd's Q1 FY27 earnings call — and how it ranks against sector…
Softtech Engineers Ltd (Q1 FY27)
Revenue from Operations (Standalone) for Q1 FY27: INR 3,222.02 Lakhs, up 25.0% YoY from INR 2,578.58 Lakhs in Q1 FY26 . Key concall takeaways from Softtech…
Tanla Platforms Ltd (Q1 FY27)
Revenue for Q1 FY27: ₹12,264 Mn, up 17.8% YoY and 4.1% QoQ (Pages 3, 7, 21). Key concall takeaways from Tanla Platforms Ltd's Q1 FY27 earnings call — and how…
ASM Technologies Ltd (Q4 FY26)
Revenue from Operations for Q4 FY26: ₹135.1 Cr, up 18.0% YoY from ₹114.5 Cr in Q4 FY25 (Page 8). Key concall takeaways from ASM Technologies Ltd's Q4 FY26…

Compare:vs Tata Consultancy Services Ltd vs Infosys Ltd vs HCL Technologies Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →